Jason P Rhodes, Director, on June 23, 2026, sold 267,760 shares in Dyne Therapeutics (DYN) for $5,646,497. Following the Form 4 filing with the SEC, Rhodes has control over a total of 1,089,006 common shares of the company, with 1,089,006 controlled indirectly.
SEC Filing:
Price: $21.20, Change: $+0.59, Percent Change: +2.86%
Robert P. Farrell, President, Communication and Computing, on June 23, 2026, sold 2,920 shares in TTM Technologies (TTMI) for $612,598. Following the Form 4 filing with the SEC, Farrell has control over a total of 16,486 common shares of the company, with 16,486 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1116942/000119312526283125/xslF345X05/ownership.xml
Daniel L. Boehle, Executive Vice President and CFO, on June 23, 2026, sold 6,341 shares in TTM Technologies (TTMI) for $1,330,307. Following the Form 4 filing with the SEC, Boehle has control over a total of 72,922 common shares of the company, with 72,922 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1116942/000119312526283127/xslF345X05/ownership.xml
Dale Martin Knecht, Senior Vice President, Information Technology, on June 23, 2026, sold 6,754 shares in TTM Technologies (TTMI) for $1,416,952. Following the Form 4 filing with the SEC, Knecht has control over a total of 68,350 common shares of the company, with 68,350 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1116942/000119312526283121/xslF345X05/ownership.xml